Methylprednisolone Taper Reduces Posttraumatic Headache Severity After Mild TBI

New findings presented at the 2026 American Academy of Neurology (AAN) Annual Meeting suggest that short-course methylprednisolone tapers may help reduce headache severity in patients with acute posttraumatic headache (PTH) following mild traumatic brain injury (mTBI), offering clinicians a potential early intervention strategy in a population where evidence-based pharmacologic options remain limited.¹

In a retrospective cohort study presented by Arielle Lehman, MD, director of the Sports Neurology and Concussion Program at Weill Cornell Medicine, treatment with a 6-day oral methylprednisolone taper was associated with statistically significant reductions in headache severity scores among patients with acute PTH. The findings also highlighted the role of mood and sleep disturbances in concussion recovery and treatment response.

“Posttraumatic headache is one of the most common and disabling sequelae of mild traumatic brain injury, yet we lack high-quality evidence-based acute treatments,” Lehman said in an interview with NeurologyLive®. “A lot of the pharmacologic management of posttraumatic headache remains almost entirely off-label and extrapolated from primary headache disorders, but posttraumatic headache is biologically distinct from those conditions.”

The study evaluated 50 patients with acute PTH after mTBI who received a standard methylprednisolone taper regimen. Patients rated headache severity using a 7-point Likert scale before and after treatment, while investigators also assessed headache frequency, PTH phenotype, preinjury headache history, and concurrent medication use.

According to the presented data, mean headache severity scores improved from 3.91 before treatment to 2.58 after treatment (t = 5.3; P <.01), representing a statistically significant reduction. Investigators also observed reductions in the proportion of patients experiencing daily headaches. Lehman noted that these improvements may hold meaningful clinical relevance for patients recovering from concussion, even if traditional migraine-style treatment benchmarks are not met.

“For someone in this acute post-concussion window, shifting from severe daily headache to a milder, more tolerable pain can make the difference between being sidelined and being able to return to work, school, or graded aerobic activity,” she said.

Subgroup analyses revealed differences in treatment response among patients with neurobehavioral comorbidities. Patients without depression demonstrated more pronounced improvements in headache severity compared with those with depression, while individuals with mood or sleep disturbances also showed measurable benefit following treatment.

Specifically, patients without depression improved from a mean headache severity score of 3.72 to 2.14 post-treatment, whereas patients with depression showed less change, from 4.67 to 4.33. Significant reductions were also observed among patients with mood disturbances and sleep dysfunction.

READ MORE:

“These findings suggest that depression and sleep disturbance may moderate treatment response, potentially blunting the magnitude of improvement that we see,” Lehman explained. “But I would not interpret the results as indicating that these patients should be excluded from treatment. Rather, it highlights that headache severity in this population is often embedded in a broader neurobehavioral context, and a multimodal approach may be necessary to optimize outcomes.”

The study also reflected broader challenges in researching concussion and posttraumatic headache populations. Lehman explained that concussion recovery can occur naturally over time, making it difficult to distinguish treatment-related effects from spontaneous improvement. In addition, concussion presentations are highly heterogeneous, with patients often exhibiting varying combinations of physical, cognitive, behavioral, and sleep-related symptoms.

Currently, no FDA-approved therapies exist specifically for posttraumatic headache, and most treatment approaches are adapted from migraine management strategies. Lehman said she currently views methylprednisolone tapers as a potential “bridge intervention” during the acute recovery phase, particularly for patients with substantial symptom burden.

“I see the methylprednisolone taper as an early bridge intervention in the acute phase, particularly for patients with higher symptom burdens or daily functioning-limiting headaches,” Lehman said. “An important unanswered question is whether early anti-inflammatory intervention could reduce the risk of transition from acute to persistent posttraumatic headache.”

She added that future studies may help clarify whether early anti-inflammatory approaches can interrupt the inflammatory cascade and central sensitization thought to contribute to persistent posttraumatic headache development.

Click here for more AAN 2026 coverage.

REFERENCE
1. Lehman A, et al. Efficacy of methylprednisolone taper in treating posttraumatic headache. Presented at: 2026 American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago, Illinois. Abstract 3-004.